Deal unites clinical diagnostic powerhouse with high-profile consumer platform, creating an integrated epigenetics-driven longevity model.
Infinite Epigenetics is acquiring Tally Health in what is the largest consolidation to date in the epigenetic age testing space. By folding the Sinclair-founded, consumer-focused longevity brand into their existing diagnostic infrastructure, Infinite (which is the parent company of TruDiagnostic) isn’t just buying market share; they’re trying to own the entire feedback loop, from the initial cheek swab to the specific supplements meant to move the needle on the results.
While Tally, which was co-founded by Harvard geneticist Dr David Sinclair, retains its branding and CEO Melanie Goldey, the play here is about scale. Dr Matthew Dawson remains at the helm of the combined group, with an ambition that goes well beyond the current market: he wants to move epigenetics from a research curiosity into a standard, data-driven pillar of preventive healthcare by plugging Tally’s consumer reach into Infinite’s clinical-grade scientific engine.
Longevity.Technology: This deal is a statement of intent: Infinite isn’t just measuring aging anymore – they’re aiming to own the whole loop from the raw data to the actual intervention. For years, epigenetic testing has sat in an awkward limbo: it’s fascinating and data-rich, sure, but it’s always struggled to prove consistent clinical utility. The gamble here is that by welding their massive proprietary datasets to Tally’s consumer pipeline, they’ll finally force the science into something truly actionable. It’s an efficient play, but it also creates a closed ecosystem that blurs the line between medical insight and commercial incentive – a tension that’s quickly becoming the defining feature of this industry. The question has shifted. It’s no longer about whether we can capture a snapshot of aging; it’s about whether we can actually move the needle, and prove it. To discuss the mechanics of the deal and the future of the platform, we sat down with Tally Health CEO Melanie Goldey and Infinite Epigenetics CEO Dr Matthew Dawson
Moving from measurement to health impact
For Tally Health CEO Melanie Goldey, the acquisition solves the “so what?” problem of biological age testing, and is an opportunity to strengthen a loop that the company has been building since its inception. While critics often point to the gap between biological age scores and actual clinical outcomes, Goldey argues that “measurement alone isn’t enough” and that longevity is largely shaped by lifestyle and daily behaviors.
“If you can measure how someone is aging, personalize the right interventions, and track change over time, you can help people become more active participants in their own healthspan,” she says. “In our internal longitudinal data, we have seen that, on the whole, our customers improve both their lifestyle and epigenetic age.”
The integration with Infinite Epigenetics is designed to provide the clinical weight needed to back those consumer experiences. Goldey believes the access to larger datasets and scientific infrastructure will make Tally’s insights more precise. “The opportunity is not to move Tally from testing into intervention – we’re already there,” she explains. “The opportunity is to make that loop more powerful: better data, deeper personalization, more targeted products, and a stronger evidence base around what meaningfully improves healthspan over time.”
Navigating the tension of scientific rigor
As the longevity field explodes in popularity, the risk of “science-washing” commercial products remains a constant concern. Goldey is adamant that Tally’s mission is to translate advanced science responsibly rather than diluting it for marketing purposes. She notes that the company has already published 14 peer-reviewed papers and expects the scientific bar to rise under the new ownership.
“As Tally scales within Infinite Epigenetics, the scientific bar goes up, not down,” Goldey asserts. “We now have access to deeper infrastructure, broader datasets, and greater ability to test and refine our approach over time.” She notes that Infinite brings a network of over 115 academic partnerships with institutions like Harvard and Yale. “Not every signal will become a product claim. Not every correlation will become guidance. The power of this platform is that we can continuously pressure-test what we are seeing against real-world data.”
Precision over correlation
While thousands of epigenetic clocks exist, Infinite Epigenetics CEO Dr Matthew Dawson emphasizes that his platform focuses exclusively on those with “rigorous validation,” such as the DunedinPACE and OMICmAge clocks. He views these metrics as the foundation for a much broader diagnostic shift.
“Our focus is on using epigenetic data to develop clinically relevant insights across health systems and biological function,” Dawson says. “Over time, our goal is to help epigenetics become a practical layer of modern diagnostics: not simply telling someone whether they appear ‘older’ or ‘younger’ biologically, but helping clinicians understand what is changing biologically, where risk may be emerging, and how to intervene earlier.”
Dawson believes the scale of their combined DNA methylation dataset – now the largest private collection of its kind – is only useful if it improves decision-making. By using AI to process this data, the company aims to move beyond simple correlations. “The objective isn’t to generate more insights – it’s to generate better decisions about what works, for whom, and under what conditions,” he says.
The closed-loop dilemma
The merger creates a triple threat – a vertically integrated system where the same entity provides the test, the analysis and the intervention. Addressing concerns about potential bias, Dawson points to the structural separation between the brands: Tally will handle the consumer interventions while Infinite and TruDiagnostic manage the scientific and diagnostic backbone.
“That structure matters because it preserves channel clarity and helps ensure recommendations are not simply a mechanism to push products,” Dawson explains. He argues that the platform’s ultimate value hinges on its ability to prove impact, which requires an objective evidence-based approach. “If an intervention – whether it’s a supplement, a lifestyle change, or something else – doesn’t produce a meaningful effect, the data has to inform that. Credibility in this field won’t come from owning more of the stack; it will come from proving what works.”
